CytoSorbents has entered into an exclusive distribution agreement with Hitit Medical Systems for the latter to distribute CytoSorb in Turkey. The initial term of the agreement is three years, and is subject to annual minimum guaranteed orders of CytoSorb to maintain exclusivity.
CytoSorb was launched in the EU in 2012. Vincent Capponi, CytoSorbents' C, stated that Turkey, with its modern medical facilities and infrastructure in accredited hospitals and common use of blood purification technologies, is an ideal first country to target outside the EU.
CytoSorb, the company's flagship product, is approved in the EU as a safe and effective extracorporeal cytokine filter, designed to reduce the cytokine storm that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. CytoSorb also removes myoglobin from blood, making it a potential treatment of rhabdomyolysis in trauma.